4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout

Four large pharmaceutical companies have continued raising dividends despite looming patent expirations on blockbuster drugs worth billions of dollars in lost exclusivity. The article contrasts their payout resilience with smaller pharma companies whose dividends have been undermined by patent cliffs, signaling stronger cash-flow durability and capital-return capacity among the Big Pharma group.